Elanco Animal Health Incorporated (ELAN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance, optimistic guidance, and strategic growth initiatives. The raised guidance for 2025 and innovation revenue increase are positive indicators. The Q&A reveals confidence in Zenrelia's international success and expected FDA label updates, which could enhance U.S. market prospects. The company's competitive positioning and strong distributor relationships further support growth. Despite some vague responses, the overall sentiment is positive, likely leading to a stock price increase.
Key Financial Performance
Organic constant currency revenue growth 9% in Q4 2025, driven by U.S. Farm Animal up 17% and U.S. Pet Health up 10%. Growth attributed to strong performance across geographies and species.
Innovation revenue $892 million for 2025, exceeding expectations. Growth driven by contributions across geographies, species, and products.
Net leverage ratio Improved to 3.6x at year-end 2025, faster than planned. Improvement due to strong cash focus and results.
U.S. Pet Health revenue Up 10% in Q4 2025, driven by Credelio Quattro and Zenrelia, with broader portfolio benefits and healthy OTC parasiticide dispensing trends.
International Pet Health revenue Up 8% in Q4 2025, driven by Zenrelia, Credelio, and Adtab. Strong performance in Europe, the U.K., and Australia.
U.S. Farm Animal revenue Up 17% in Q4 2025, led by Experior and Pradalex, with contributions from poultry.
International Farm Animal revenue Up 4% in Q4 2025, driven by ruminants, swine, and poultry.
Adjusted gross margin 51.2% in Q4 2025, up 30 basis points YoY. Improvement due to price, increased sales volumes, and mix benefits.
Adjusted EBITDA $189 million in Q4 2025, up 7% YoY. Growth driven by revenue increase and operational efficiencies.
Adjusted EPS $0.13 in Q4 2025, down 7% YoY. Decline due to higher tax rate from timing of one-time benefits.
Full-year revenue $4.715 billion for 2025, up 6% YoY. Growth driven by innovation and strong performance across top product franchises and geographies.
Experior revenue Up 35% in Q4 2025 and nearly 80% for the full year, crossing $200 million. Growth driven by U.S. cattle market dynamics and adoption.
Adtab revenue Up more than 50% in 2025. Fastest-growing brand in the $600 million OTC ecto market in Europe, achieving over 50% oral OTC share.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Credelio Quattro: Fastest blockbuster in Elanco's history, gaining share in the U.S. broad-spectrum parasiticide market and expanding globally with approval in Australia.
Zenrelia: Strong performance in the $2 billion derm market, achieving double-digit share in the U.S. and international markets like Brazil, Japan, and Europe.
Befrena: USDA approval received, launch expected in Q2 2026, offering differentiation in convenience and efficacy.
Adtab: Fastest-growing brand in the $600 million OTC ecto market in Europe, achieving over 50% oral OTC share.
Experior: Continued growth, crossing $200 million in 2025, with potential market of over $350 million in the U.S. and Canada.
AHV International Acquisition: Acquisition of Dutch-based farm animal health innovator to expand leadership in the dairy industry, particularly in North America and Europe.
Global Expansion of Credelio Quattro: Entering the $700 million international market for broad-spectrum parasiticides, starting with Australia.
Zenrelia International Growth: Strong traction in Europe, U.K., and Australia, achieving significant market share in key regions.
Elanco Ascend: Company-wide productivity initiative to drive efficiencies and margin enhancement, with $25 million in savings expected in 2026.
Debt Reduction: Improved net leverage ratio to 3.6x in 2025, with a target of 3.1x to 3.3x in 2026.
Focus on Innovation: Commitment to at least $1.15 billion in innovation revenue in 2026, with a pipeline of 5-6 blockbuster potential approvals expected through 2031.
Omnichannel Pet Health Strategy: Targeting modern pet owners with a strategy to meet their preferences for access, convenience, and spending.
Farm Animal Protein Demand: Capitalizing on increasing global animal protein consumption, projected to grow at 5% annually in the U.S.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive Pressures: Acknowledged competitive pressures in the Pet Health market, including generics, which could impact market share and revenue growth.
Regulatory Challenges: Mentioned the need to align U.S. labels with international standards for Zenrelia, indicating potential regulatory hurdles.
Supply Chain and Manufacturing: Phased launch of Befrena due to manufacturing ramp-up challenges, which could delay revenue realization.
Economic Uncertainties: Dynamic macro environment acknowledged, which could impact pricing strategies and overall financial performance.
Debt and Financial Leverage: High net leverage ratio of 3.6x, with a target to reduce it below 3x by 2027, indicating financial constraints.
Market Dynamics in Farm Animal Sector: Dependence on favorable producer economics and accelerating animal protein consumption, which are subject to market fluctuations.
Innovation and R&D Risks: Pressure to maintain a consistent flow of high-impact innovation while managing R&D costs and timelines.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Innovation Revenue: Raised outlook to $1.15 billion, reflecting contributions across geographies, species, and products.
Net Leverage Ratio: Expected to finish 2026 at 3.1x to 3.3x.
2026 Organic Constant Currency Revenue Growth: Projected at 4% to 6%.
Adjusted EBITDA: Forecasted at $955 million to $985 million, representing 8% growth at the midpoint.
Adjusted EPS: Expected to be $1 to $1.06, representing 10% growth at the midpoint.
Big 6 Innovation Products: Expected to double revenue from 2025 to 2028.
Credelio Quattro: Global rollout begins in 2026, starting with approval in Australia.
Zenrelia: Momentum building with strong international traction; expected to continue growth in 2026.
Befrena: Launch expected in Q2 2026 after manufacturing ramp-up.
Adtab: Continued robust growth trajectory, with sales up more than 50%.
Experior: Significant runway ahead with potential market of over $350 million in the U.S. and Canada.
Bovaer: Long-term blockbuster potential with near-term growth at a measured pace.
Elanco Ascend: Productivity initiative expected to drive meaningful efficiencies and margin enhancement starting in 2026.
Farm Animal Business: Clear runway for growth driven by new cattle products, favorable producer economics, and accelerating animal protein consumption.
Pet Health Business: Incremental share gains expected by leveraging comprehensive portfolio and OTC retail leadership.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the ramping international Zenrelia share gains and what that may mean for the U.S. if the label is altered positively?
A:Jeffrey Simmons highlighted that Zenrelia's efficacy is driving its success internationally, with over 30% market share in Japan and 40% in Brazil. In Europe, despite new competition, Zenrelia continues to gain market share. The product has been used in 40 countries with clean labels and good pharmacovigilance data. They are optimistic about receiving a positive response from the FDA regarding label changes.
Q:What are your thoughts on the Covetrus and MWI merger and its implications for Elanco?
A:Jeffrey Simmons stated that Elanco has strong relationships with distributors, which are beneficial for launching new products. He emphasized Elanco's competitive advantage with a comprehensive portfolio and buy-sell agreements. The company gained market share in all U.S. Pet Health categories in 2025, attributing some of this success to distributors.
Q:Can you quantify the expected price acceleration in 2026 compared to 2025?
A:Robert VanHimbergen explained that price growth is expected to accelerate from 2% in 2025, reflecting the enhanced value of innovation and the comprehensive portfolio. Launches in 2025, which did not contribute to price, will have a pricing component in 2026, contributing to the expected price acceleration.
Q:How is Quattro contributing to the broader portfolio and competitive positioning?
A:Jeffrey Simmons noted that Quattro is performing well, with over 75% of sales being new starts. It has driven additional product purchases in 2,600 clinics and gained confidence among corporate accounts. The product's differentiation and portfolio effect are expected to strengthen Elanco's competitive position.
Q:Are there any stocking or destocking dynamics affecting the quarter or seasonal purchasing trends?
A:Jeffrey Simmons stated that there were no significant stocking or destocking effects. Distributors are ordering multiple times per quarter, reflecting strong dispensing demand from clinics.
Q:What is the timeline for the label update for Zenrelia in the U.S.?
A:Jeffrey Simmons mentioned that they are in constructive dialogue with the FDA and are confident in the data submitted. They expect the label to align more closely with other countries and are awaiting an FDA response.
Q:How is Zenrelia performing in Europe compared to competitors?
A:Jeffrey Simmons stated that Zenrelia's efficacy is highly recognized in Europe, with strong initial market penetration and usage as a first-line treatment in major countries like France, Italy, and Spain. The product is performing better than expected for a second or third-to-market product.
Q:What are the assumptions behind the 2026 guidance and the outlook for the livestock business?
A:Robert VanHimbergen explained that the 2026 guidance assumes mid-single-digit growth, with stable base business trends. Jeffrey Simmons highlighted favorable cattle producer economics and growth in dairy and poultry markets, which are expected to contribute to the livestock business.
Q:What is driving the growth in the derm market internationally?
A:Jeffrey Simmons noted double-digit growth in the derm market, driven by increased promotion and new starts, particularly in Europe and international markets where 70% of new puppies are located.
Q:Is the 2026 guidance balanced between pet and farm segments?
A:Robert VanHimbergen stated that the 2026 guidance is generally balanced across quarters and between pet and farm segments, with farm business expected to grow mid-single digits and pet slightly higher.
Q:What is the outlook for gross margin in 2026?
A:Robert VanHimbergen stated that gross margin is expected to expand by 40 basis points in 2026, driven by price acceleration, innovation, and operational improvements. However, inflation and higher cost inventory will impact the first half of the year.
Q:What is the expected contribution of the Credelio franchise to 2026 growth?
A:Jeffrey Simmons indicated that the Credelio franchise, particularly Quattro, is expected to be a major contributor to 2026 growth, along with Zenrelia and Befrena.
Q:What is the progress in gaining corporate accounts and addressing portfolio gaps?
A:Jeffrey Simmons highlighted significant progress in corporate accounts, with nearly all U.S. clinics engaged and strong growth in Europe. The addition of Befrena and focus on international pet vaccines are expected to further strengthen their position.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines for the FDA's response on the Zenrelia label update and did not quantify the exact contribution of Credelio to 2026 growth. Additionally, they used general terms like 'constructive dialogue' and 'confident' without providing detailed data or timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AHV
Adtab
Australia
Befrena
EU
Europe
Health currency
International
Investor Relations
JAK market
OTC
Pet Health
Quattro
RD
Slide currency
animal health
approval
benefit
contribution
digit
efficacy
efficiency
engine
flow
label
launch
leverage
manufacturing
midpoint
momentum
parasiticide
portfolio
poultry
price
ruminant
spectrum
tax
vet clinic
volume
year
ELAN Transcript
Elanco Animal Health Incorporated (ELAN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
Elanco Animal Health Incorporated (ELAN) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call summary and Q&A indicate strong financial performance, optimistic guidance, and strategic growth initiatives. The raised guidance for 2025 and innovation revenue increase are positive indicators. The Q&A reveals confidence in Zenrelia's international success and expected FDA label updates, which could enhance U.S. market prospects. The company's competitive positioning and strong distributor relationships further support growth. Despite some vague responses, the overall sentiment is positive, likely leading to a stock price increase.
Elanco Animal Health Incorporated (ELAN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Tecsys Inc. (TCS:CA) Q2 2026 Earnings Call Transcript
Unknown12-4
The earnings call highlights strong SaaS and professional services revenue growth, improved margins, and a healthy cash position, which are positive indicators. However, concerns about elongated decision cycles, attrition in noncore customers, and macroeconomic challenges like tariffs and healthcare policy create uncertainties. The Q&A section reveals cautious management responses and elongated deal cycles, adding to the mixed sentiment. Despite financial strength, the uncertainties and cautious outlook balance the positive aspects, leading to a neutral sentiment prediction for the stock price over the next two weeks.
ELAN Slides
Elanco Q4 2025 slides: innovation drives growth, debt falls faster2026-02-24
Elanco Q3 2025 slides: Innovation drives 9% revenue growth, guidance raised2025-11-05
Elanco Q2 2025 slides: 8% organic growth drives raised guidance despite headwinds2025-08-07
Elanco Q1 2025 slides: Revenue guidance raised amid innovation-driven growth2025-05-07
ELAN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
